Medical device company Sequana names new chairman

Switzerland-based Sequana Medical has appointed a new chairman to their board of directors as the company expands its international commercialization of its fluid pump.

Sequana named Rolf Classon, a former top executive of Germany-based Bayer, chairman of the board, the company announced in a statement today. 

"We are delighted to welcome Rolf in the key position of chairman," said Noel Johnson, CEO of Sequana Medical. "His extensive experience as a senior officer and board member of a number of international medical device, pharmaceutical and biotechnology companies, gives him an excellent vantage point from which to help steer Sequana Medical in the next phase of its growth."

Sequana is a commercial medical device company known for its alfapump system, an implantable battery-powered pump that manages abdomen fluid build-up.

Classon also serves on the boards of Catalent Pharma Solutions, Fresenius Medical Care, Hill-Rom Holdings and Tecan Goup. He was the interim president and CEO of Batesville, Ind.-based Hillenbrand Industries from 2005-2006.

Katherine Davis,

Senior Writer

As a Senior Writer for TriMed Media Group, Katherine primarily focuses on producing news stories, Q&As and features for Cardiovascular Business. She reports on several facets of the cardiology industry, including emerging technology, new clinical trials and findings, and quality initiatives among providers. She is based out of TriMed's Chicago office and holds a bachelor's degree in journalism from Columbia College Chicago. Her work has appeared in Modern Healthcare, Crain's Chicago Business and The Detroit News. She joined TriMed in 2016.

Around the web

RBMA President Peter Moffatt discusses some of the biggest obstacles facing the specialty in the new year. 

Mark Isenberg, executive vice president of Zotec Partners, discusses key developments that will reshape the specialty this year. 

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.